Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Darren Hart¹, Ginger L. Milne² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…
Abstract Number: 682 • 2013 ACR/ARHP Annual Meeting
Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study
Shinichiro Saito¹, Yukiko Kamogawa², Kyohei Nakamura³, Ryu Watanabe³, Tsuyoshi Shirai², Yoko Fujita⁴, Hiroshi Fujii³, Yuko Shirota⁵, Tomonori Ishii³, Hideo Harigae³, Katsuko Kikuchi⁶ and Yasushi Kawaguchi⁷, ¹Department of hematology and rheumatology, Tohoku University, Sendai, Japan, ²Tohoku University, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁴Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁶Department of Dermatology, Tohoku University, Sendai, Japan, ⁷Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Vasculopathy, immunological abnormalities and excessive tissue fibrosis are key elements in the pathogenesis of Scleroderma (SSc). In winter, patients often display Raynaud syndrome, which…
Abstract Number: 1519 • 2012 ACR/ARHP Annual Meeting
Heterogeneous Nuclear RNP-K Is a Novel Cold-Related Autoantigen in Patients with Raynaud’s Phenomenon
Satoshi Serada¹, Minoru Fujimoto² and Tetsuji Naka², ¹Laboratory for immune signal, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan, ²Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan
Background/Purpose: Raynaud’s phenomenon (RP) is a vasospastic disorder and shows discoloration of the fingers, toes, and occasionally other areas. RP affects 3-9% of the general…
Abstract Number: 1484 • 2012 ACR/ARHP Annual Meeting
Investigating Determinants of Subjective and Objective Assessments of Peripheral Vascular Function in Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Nigel Harris² and Neil McHugh², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The Raynaud’s condition score (RCS) diary is recommended for use in clinical trials of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We report the…
Abstract Number: 1495 • 2012 ACR/ARHP Annual Meeting
Platelet Aggregability, Eicosanoid Biosynthesis and Oxidative Stress in Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹ and Neil McHugh², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Increased platelet activation, endothelial dysfunction and oxidative stress are all thought to contribute to the pathogenesis of Raynaud’s phenomenon (RP), particularly in the context…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].